12,800 Shares in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Bought by Fisher Asset Management LLC

Fisher Asset Management LLC bought a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,800 shares of the company’s stock, valued at approximately $51,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals during the third quarter valued at $47,000. Miller Investment Management LP grew its stake in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after purchasing an additional 49,640 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Citius Pharmaceuticals during the third quarter worth about $50,000. Chelsea Counsel Co. grew its stake in shares of Citius Pharmaceuticals by 9.8% during the third quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after acquiring an additional 25,000 shares during the last quarter. Finally, IFP Advisors Inc grew its stake in shares of Citius Pharmaceuticals by 21.2% during the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock worth $162,000 after acquiring an additional 7,083 shares during the last quarter. 16.88% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, February 18th.

Citius Pharmaceuticals Price Performance

NASDAQ CTXR opened at $1.79 on Friday. The business has a fifty day moving average price of $2.82 and a 200 day moving average price of $6.77. Citius Pharmaceuticals, Inc. has a one year low of $1.47 and a one year high of $26.75.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). On average, equities research analysts expect that Citius Pharmaceuticals, Inc. will post -4.5 earnings per share for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.